S. R. Schill & Associates purchased a new position in shares of Celgene Corporation (NASDAQ:CELG) during the first quarter, Holdings Channel reports. The firm purchased 2,082 shares of the biopharmaceutical company’s stock, valued at approximately $259,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. State Street Corp increased its stake in Celgene Corporation by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock worth $4,040,668,000 after buying an additional 723,844 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Celgene Corporation by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock worth $1,255,309,000 after buying an additional 472,067 shares during the last quarter. American Century Companies Inc. increased its stake in Celgene Corporation by 4.4% in the first quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock worth $816,733,000 after buying an additional 276,089 shares during the last quarter. Pioneer Investment Management Inc. increased its stake in Celgene Corporation by 15.7% in the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock worth $650,911,000 after buying an additional 710,584 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in Celgene Corporation by 4.3% in the first quarter. Legal & General Group Plc now owns 3,587,623 shares of the biopharmaceutical company’s stock worth $446,406,000 after buying an additional 147,263 shares during the last quarter. 78.34% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Celgene Corporation (NASDAQ CELG) traded down 1.39% during trading on Thursday, reaching $129.44. 1,503,329 shares of the company’s stock traded hands. The stock has a 50-day moving average of $134.04 and a 200-day moving average of $124.79. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $139.00. The company has a market capitalization of $101.27 billion, a price-to-earnings ratio of 40.09 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business’s quarterly revenue was up 18.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.44 earnings per share. On average, equities analysts predict that Celgene Corporation will post $7.32 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/08/17/s-r-schill-associates-purchases-shares-of-2082-celgene-corporation-celg.html.

CELG has been the subject of a number of recent research reports. Jefferies Group LLC set a $154.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a report on Saturday, May 13th. Vetr downgraded shares of Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $132.90 price objective for the company. in a report on Thursday, May 11th. BTIG Research reiterated a “buy” rating and issued a $138.00 price objective on shares of Celgene Corporation in a report on Monday, May 1st. Cantor Fitzgerald set a $159.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a report on Thursday, April 27th. Finally, Cann reiterated a “buy” rating on shares of Celgene Corporation in a report on Thursday, April 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $147.00.

In other news, insider Rupert Vessey sold 4,785 shares of the company’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the transaction, the insider now directly owns 4,004 shares in the company, valued at $481,200.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gilla Kaplan sold 7,500 shares of the company’s stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the completion of the transaction, the director now owns 76,301 shares of the company’s stock, valued at $10,264,010.52. The disclosure for this sale can be found here. Insiders sold 253,761 shares of company stock valued at $33,792,445 over the last 90 days. Insiders own 0.95% of the company’s stock.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.